GGrantIndex
← Search

CANCER GENETICS AND EPIGENETICS

$76,081P30FY2011CANIH

Emory University, Atlanta GA

Investigators

Linked publications, trials & patents

Trial NCT07405476Trial NCT07213154Trial NCT07174570Trial NCT07155317Trial NCT07150546Trial NCT07140679Trial NCT07112690Trial NCT07104240Trial NCT07101445Trial NCT06914999Trial NCT06868433Trial NCT06865768Trial NCT06799481Trial NCT06760507Trial NCT06731270Trial NCT06709534Trial NCT06708351Trial NCT06674863Trial NCT06662058Trial NCT06650579Trial NCT06636734Trial NCT06595160Trial NCT06583148Trial NCT06541158Trial NCT06534125Trial NCT06495125Trial NCT06492759Trial NCT06492070Trial NCT06423326Trial NCT06328699Trial NCT06328686Trial NCT06324240Trial NCT06254911Trial NCT06132685Trial NCT06105918Trial NCT06008730Trial NCT06006013Trial NCT05998135Trial NCT05877859Trial NCT05873608Trial NCT05798507Trial NCT05779943Trial NCT05756569Trial NCT05733351Trial NCT05526872Trial NCT05514912Trial NCT05513859Trial NCT05506982Trial NCT05493566Trial NCT05488145Trial NCT05464810Trial NCT05391750Trial NCT05387915Trial NCT05368428Trial NCT05346692Trial NCT05341349Trial NCT05320406Trial NCT05315687Trial NCT05310448Trial NCT05274763Trial NCT05250895Trial NCT05245682Trial NCT05244239Trial NCT05208307Trial NCT05204160Trial NCT05103904Trial NCT05091866Trial NCT05086731Trial NCT05039073Trial NCT05017610Trial NCT04908709Trial NCT04895592Trial NCT04890236Trial NCT04883437Trial NCT04878029Trial NCT04848519Trial NCT04776395Trial NCT04762199Trial NCT04754945Trial NCT04750473Trial NCT04731376Trial NCT04725903Trial NCT04676087Trial NCT04590664Trial NCT04585724Trial NCT04524702Trial NCT04483206Trial NCT04433949Trial NCT04428671Trial NCT04393350Trial NCT04366791Trial NCT04361552Trial NCT04352205Trial NCT04348292Trial NCT04340882Trial NCT04278118Trial NCT04276194Trial NCT04262869Trial NCT04191421Trial NCT04144127

Abstract

Program 1. Cancer Genetics and Epigenetics (CGE): DNA damage, genetic mutations, genomic instability and alterations in DNA/chromatin modifications that modify gene expression are all critical events that contribute to the development of cancers in humans. The primary themes of the CGE Program reflect a major emphasis on basic science investigations directly related to oncogenesis. The CGE Program's four main thematic areas are: (1) DNA damage, repair, mutagenesis and genetic instability;(2) epigenetics, including DNA and chromatin modification and chromatin remodeling;(3) chromosome instability and nuclear architecture;(4) cancer genetics and functional genomics. The aims of the CGE Program are: (1) To elucidate the underlying molecular and biochemical mechanisms that result in the establishment and maintenance of genetic instability during tumor development and progression. (2) To elucidate and understand how epigenetic modifications of DNA and chromatin structural components impact gene expression programs and other nucleic acid transactions during tumorigenesis. (3) To understand the mechanisms underlying chromosomal aberrations, allelic imbalances and alterations in nuclear architecture and their contributions to multi-step tumorigenesis. (4) To identify and characterize novel oncogenes and tumor suppressor genes and to develop genome-scale discovery and analysis platforms and computational models to identify genetic loci and genetic variants involved in tumorigenesis. The CGE Program is comprised of 26 members from 10 departments within the School of Medicine and Emory College. Currently, there are 24 funded program members with total support of approximately $9 million per year, of which NCI funding represents $3.9M ($2.6M direct). From 2003-2008 the CGE program members published 400 articles. Of these total publications, 39 (9.75%) are intraprogrammatic collaborations and 82 (20.5%) are interprogrammatic collaborations. From 2006-2008, CGE members published 183 articles. Intraprogrammatic collaborations account for 21 (11.5 %) and interprogrammatic collaborations account for 39 (21.3 %) of these publications.

View original record on NIH RePORTER →